- Home
- HYLN vs NNNN Comparison
HYLN vs NNNN Comparison
Compare HYLN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- NNNN
- Stock Information
- Founded
- HYLN 2018
- NNNN 2021
- Country
- HYLN United States
- NNNN Germany
- Employees
- HYLN N/A
- NNNN N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HYLN Consumer Discretionary
- NNNN Health Care
- Exchange
- HYLN Nasdaq
- NNNN Nasdaq
- Market Cap
- HYLN 279.7M
- NNNN 267.7M
- IPO Year
- HYLN N/A
- NNNN 2025
- Fundamental
- Price
- HYLN $1.64
- NNNN $6.43
- Analyst Decision
- HYLN Hold
- NNNN
- Analyst Count
- HYLN 1
- NNNN 0
- Target Price
- HYLN $2.00
- NNNN N/A
- AVG Volume (30 Days)
- HYLN 659.3K
- NNNN 28.8K
- Earning Date
- HYLN 05-13-2025
- NNNN 01-01-0001
- Dividend Yield
- HYLN N/A
- NNNN N/A
- EPS Growth
- HYLN N/A
- NNNN N/A
- EPS
- HYLN N/A
- NNNN 0.06
- Revenue
- HYLN $1,509,000.00
- NNNN $8,185,146.00
- Revenue This Year
- HYLN $741.55
- NNNN N/A
- Revenue Next Year
- HYLN $185.14
- NNNN N/A
- P/E Ratio
- HYLN N/A
- NNNN $118.17
- Revenue Growth
- HYLN 124.55
- NNNN 21.95
- 52 Week Low
- HYLN $1.17
- NNNN $5.18
- 52 Week High
- HYLN $4.10
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- HYLN 56.93
- NNNN N/A
- Support Level
- HYLN $1.53
- NNNN N/A
- Resistance Level
- HYLN $1.69
- NNNN N/A
- Average True Range (ATR)
- HYLN 0.08
- NNNN 0.00
- MACD
- HYLN 0.02
- NNNN 0.00
- Stochastic Oscillator
- HYLN 79.25
- NNNN 0.00
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.